Dr. Anthony Marotta, Ph.D. is a serial entrepreneur and an Adjunct Professor in the Faculty of Medicine at the University of British Columbia. He is a clinical scientist who recognizes that impactful innovation requires rigorous science coupled with disciplined business processes, operational execution, and teams designed for scale.
Dr. Marotta has co founded several life sciences and health focused companies, including Augurex Life Sciences Corp, SignalChem Bioreagents, and Peqish Group and Food, and has served as a scientific, clinical, and business advisor to multiple organizations. During his eleven year tenure at Augurex, he was a key contributor to the development of the 14‑3‑3η biomarker programs, contributing to peer reviewed publications, international conference proceedings, and long standing collaborations with leading rheumatology key opinion leaders. His work supported the successful commercial launch of blood based diagnostics in Canada and the United States. He currently serves as Chair of the Clinical and Scientific Advisory Board at Augurex and is a key scientific and clinical contributor to Augurex’s axial spondyloarthritis program, including work associated with an FDA Breakthrough Device designation.
Previously, Dr. Marotta led business development at Stressgen Bioreagents, expanding the product portfolio through strategic collaborations while supporting operational execution. He is a Mentor in Residence and a lecturer in the I2I Innovation to Industry program at Simon Fraser University’s Beedie School of Business. Known as an out of the box thinker, he brings particular value to organizations navigating complexity, stalled growth, or critical transition points.
